Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($31.92); post-transaction worth based connected March 19, 2026 marketplace adjacent price.

• How does the size of this transaction comparison to Ticho's humanities trading activity?
  The 14,311-share merchantability exceeds the recent-period median merchantability size of 5,429.5 shares and the humanities median of 7,073 shares crossed 16 anterior merchantability transactions, reflecting a larger-than-typical disposition successful the discourse of shrinking remaining holdings.

• What was the transactional discourse and mechanics down the sale?
  The transaction progressive the workout of options followed by the contiguous merchantability of the resulting Common Stock, with nary indirect entities oregon gifts/withholding involved.

• How has Ticho's nonstop ownership changed arsenic a effect of this transaction?
  This merchantability reduced nonstop Common Stock holdings from 55,013 to 40,702 shares, a 26.01% decrease, arsenic reported successful the filing, portion Ticho continues to clasp 83,035 banal options directly, providing important aboriginal conversion capacity.

• What broader discourse is applicable for interpreting this disposition?
  Despite the sale, Ticho maintains a full beneficial involvement of astir 123,700 shares (combining nonstop holdings and options), arsenic reported successful the filing. The transaction occurred pursuing a one-year summation of 300% for Stoke Therapeutics arsenic of March 19, 2026.

* 1-year terms alteration calculated arsenic of March 19, 2026.

• Stoke Therapeutics develops antisense oligonucleotide (ASO) medicines targeting terrible familial diseases, with pb objective programs successful Dravet syndrome (STK-001) and autosomal ascendant optic atrophy (STK-002).

• The steadfast generates gross done proprietary cause improvement and strategical collaborations, including a licensing statement with Acadia Pharmaceuticals for RNA-based therapeutics.

• It serves patients affected by uncommon and terrible familial neurological disorders, focusing connected the U.S. biopharmaceutical and healthcare markets.

Stoke Therapeutics is an early-stage biotechnology institution leveraging its proprietary Targeted Augmentation of Nuclear Gene Output level to make caller RNA-based therapies for terrible familial diseases. The company’s strategy centers connected advancing its objective pipeline and forging partnerships to accelerate commercialization opportunities. With a focused attack connected uncommon neurological disorders, Stoke Therapeutics positions itself arsenic an innovator wrong the biopharmaceutical sector.